J Breast Cancer.  2009 Sep;12(3):227-228. 10.4048/jbc.2009.12.3.227.

Commentary on "The Number of Removed Lymph Nodes for an Acceptable False Negative Rate in Sentinel Node Biopsy for Breast Cancer"

• Nam SJ
• Lee SK

• KMID: 2242017
• DOI: http://doi.org/10.4048/jbc.2009.12.3.227

Abstract

No abstract available.

MeSH Terms

Biopsy
Breast
Lymph Nodes
Nitriles
Pyrethrins
Nitriles
Pyrethrins

Reference

1. Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005. 23:7703–7720.

2. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer--a multicenter validation study. N Engl J Med. 1998. 339:941–946.

3. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006. 98:599–609.

4. McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000. 18:2560–2566.

5. Martin RC 2nd, Edwards MJ, Wong SL, Tuttle TM, Carlson DJ, Brown CM, et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. Surgery. 2000. 128:139–144.

6. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006. 7:983–990.

7. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000. 18:2553–2559.

8. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993. 2:335–339.

9. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997. 349:1864–1867.

10. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994. 220:391–398.

11. Cody HS 3rd. Clinical aspects of sentinel node biopsy. Breast Cancer Res. 2001. 3:104–108.

12. Wong SL, Edwards MJ, Chao C, Tuttle TM, Noyes RD, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg. 2001. 192:684–689.

13. Dabbs DJ, Johnson R. The optimal number of sentinel lymph nodes for focused pathologic examination. Breast J. 2004. 10:186–189.

14. Woznick A, Franco M, Bendick P, Benitez PR. Sentinel lymph node dissection for breast cancer: how many nodes are enough and which technique is optimal? Am J Surg. 2006. 191:330–333.

15. Koo BY, Jeong SG, Eom TI, Kang HJ, Kim LS. The number of removed lymph nodes for an acceptable false negative rate in sentinel lymph node biopsy for breast cancer. J Breast Cancer. 2009. 12:106–112.

16. McCarter MD, Yeung H, Fey J, Borgen PI, Cody HS 3rd. The breast cancer patient with multiple sentinel nodes: when to stop? J Am Coll Surg. 2001. 192:692–697.

17. McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008. 26:5213–5219.